CHI3L1 and in situ carcinoma: Based on these initial promising results, our group conducted a validation study of CHI3L1 as prognostic biomarker in the CSF of 813 CIS patients from 15 MS centres also classified according to their conversion to MS based on clinical and radiological criteria2.